PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7696626

Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.

A Boireau·P Dubédat·F Bordier·C Peny·J M Miquet·G Durand·M Meunier·A Doble
View original source ↗Export metadata ↓

Abstract

We have investigated whether riluzole, a compound that interferes with glutamatergic (GLUergic) transmission, would protect central dopaminergic (DAergic) neurones from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced toxicity in the striatum in mice. MPTP decreased DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels. Riluzole protected against the MPTP-induced decrease in DA levels. The utilization of DA ([DOPAC+HVA]/DA) was increased after MPTP treatment, but returned to control values in mice given riluzole in combination with MPTP. Riluzole did not confer protection by inhibiting either monoamine oxidase type B activity or DA uptake. Possible mechanisms involved in the protective action of riluzole are discussed. Our results show that riluzole antagonizes the DAergic neurotoxicity of MPTP, a pro-parkinsonian neurotoxin, in mice.

Explore related subjects

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine3,4-Dihydroxyphenylacetic AcidAnimalsBrainDopamineHomovanillic AcidMaleMiceMice, Inbred C57BLMonoamine Oxidase InhibitorsParkinson Disease, SecondaryRiluzoleThiazolesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Boireau, P Dubédat, F Bordier, C Peny, J M Miquet, G Durand, M Meunier, A Doble. 1994-12-20. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.. https://pubmed.ncbi.nlm.nih.gov/7696626/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

The monoamine oxidase B (MAO-B) substrate properties and distance measurements along the N1-C4 axis of 38 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives, including seven newly synthesized MPTP analogs, were used to define the maximum size that can be accommodated by the MAO-B active site. Only those compounds measuring less than 12 A displayed significant MAO-B substrate properties. The behavior of various 4-substituted-1-cyclopropyltetrahydropyridine analogs also is discussed in terms of this N1-C4 distance parameter in an effort to understand factors which contribute to their substrate vs inactivator properties. We conclude that this distance parameter will predict the majority of substrates vs nonsubstrates with this class of compound.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗
PubMed1996

Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium (MPP+) may be endogenous neurotoxins causing nigral cell death in Parkinson's disease. These compounds inhibit mitochondrial function but, like MPP+, require accumulation in dopaminergic neurones via the dopamine reuptake system to exert toxicity. We, now, examine the substrate affinity of 14 neutral and quaternary isoquinoline derivatives (7 isoquinolines, 2 dihydroisoquinolines and 5 1,2,3,4-tetrahydroisoquinolines) for the dopamine reuptake system by their ability to inhibit the uptake of [3H]dopamine into rat striatal synaptosomes. Ten isoquinoline derivatives and MPP+ inhibited [3H]dopamine uptake in a concentration-dependent manner. Only 5 isoquinoline derivatives produced 50% inhibition of [3H]dopamine uptake (IC50 = 8.0-50.0 microM), none of which were as potent as MPP+ (IC50 = 0.33 microM). These findings suggest that isoquinoline derivatives are moderate to poor substrates for the dopamine reuptake system and that high concentrations of, or prolonged exposure to, isoquinoline derivatives may be necessary to cause neurodegeneration.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗
PubMed1996

Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.

Sensitivity to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) varies greatly among strains of mice. The numbers of vesicular monoamine transporters was examined in various brain regions of MPTP-sensitive (C57BL/6) and MPTP-insensitive (CD-1) mouse strains. In vivo radioligand binding to the vesicular monoamine transporter was studied using [11C]methoxytetrabenazine, and in vitro Bmax values determined using [3H]dihydrotetrabenazine autoradiography. Using either technique, no significant differences between the two strains were seen in the striatal binding of these radioligands to the vesicular monoamine transporter. The in vivo binding of radioligands to this transporter in the striatum was also not gender dependent. The relative resistance of CD-1 mice to the neurotoxic effects of peripheral MPTP administration thus does not appear to be a result of enhanced protection by higher levels of vesicular storage in dopaminergic neurons of the striatum.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine↗